You just read:

Clementia Pharmaceuticals Announces Open-Label Phase 2 Extension Study of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva

News provided by

Clementia Pharmaceuticals, Inc.

Oct 27, 2014, 07:30 ET